UltraTech Cement Ltd
ULTRACEMCOUltraTech Cement Ltd's earnings have outrun its stock. EPS grew +35.2% in a year against a −11.1% price move.
The sharpest disagreement: annual EPS moved +35.2% against a −11.1% price move — the market has not yet caught up with the delivery.
The price is building a base (6 weeks in) while the P/E sits at the 41st percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +17.2% year on year, and 174% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
UltraTech Cement Ltd trades at ₹11,000, building a base and 6 weeks into that stage. That is −5.9% against its own 200-day average. It sits at 16% of a 52-week range of ₹10,616 to ₹12,963. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is building a base — week 6 of stage 1, confirmed. At ₹11,000 it trades −5.9% versus its 200-day average and sits at 16% of its 52-week range (₹10,616–₹12,963).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +297% while the NIFTY 500 moved +273% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-08-28) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
UltraTech Cement Ltd trades at 37.6× P/E, mid-range by its own standards (41st percentile). Its long-run median P/E is 40.5×, measured across 10.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 37.6× is mid-range by its own standards (41st percentile), against a long-run median of 40.5× measured over 10.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +35.2% against a −11.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +6.7%/yr price move, ~+5.6%/yr came from earnings growth and ~+1.1 pp from the multiple (expanding); over 10y, of the +10.8%/yr price move, ~+11.7%/yr came from earnings growth and ~−0.9 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 17% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, UltraTech Cement Ltd was paying for profit growth of about 23.7% a year. Profit itself has compounded 12.7% a year over the past 10 years. Today the market pays 37.6× P/E, the 41st percentile of its own 11-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
UltraTech Cement Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −9.2% at the trough to +26.7% off a 5-quarter-old trough, ROCE holding at 13.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +16.5% | +11.9% | +14.6% | +13.4% |
| Profit | +35.6% | +17.3% | +8.4% | +12.7% |
| EPS | +35.2% | +16.5% | +7.9% | +11.9% |
| Share price | −11.1% | +9.3% | +6.7% | +10.8% |
4-Factor Sector Score
63.5/100 — rank 4 of 26 in Cement · 76% evidence confidence
UltraTech Cement Ltd scores 63.5 out of 100 against the 26 companies it is compared with in Cement, ranking 4. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 23.1 + 17.1 + 9.6 + 13.7 = 63.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
UltraTech Cement Ltd reported ₹24,648 Cr of revenue in the Jun 26 quarter, +15.9% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 13.4% a year. The last full year, FY26, came in at ₹88,512 Cr. The last four reported quarters add to ₹91,884 Cr.
FY26 revenue came in at ₹88,512 Cr (+16.5% on the year), capping 10 years at 13.4% compound. The latest quarter (Jun 26) printed ₹24,648 Cr, +15.9% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +17.7% growth against the decade's 13.4% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +17.2% over the last 4 quarters against +13.0%/yr over the last 8 — accelerating; TTM profit +26.7% vs +12.2%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
UltraTech Cement Ltd's operating margin is 20.0% in the Jun 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 17.0% to 26.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 20.0%, −1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 17.0%–26.0%.
🚨 Why the margin moved: operating margin went −0.4 pp year on year while gross margin went −0.3 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
UltraTech Cement Ltd earned ₹2,604 Cr of net profit in the Jun 26 quarter, +17.2% year on year. It is the 6th consecutive quarter of growth. Full-year FY26 profit was ₹8,188 Cr. The 10-year compound rate is 12.7%. That is 10.6% of the quarter's revenue. The same quarter a year earlier earned ₹2,221 Cr.
Jun 26 profit was ₹2,604 Cr, +17.2% year on year — the 6th consecutive quarter of growth. On the full year, FY26 printed ₹8,188 Cr (+35.6%), and the 10-year compound rate is 12.7%.
Why profit moved: revenue contributed +15.9% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +35.1% vs revenue +17.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 174% of UltraTech Cement Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹15,316 Cr of operating cash against ₹8,188 Cr of profit. After ₹11,382 Cr of capital spending, ₹3,934 Cr was left as free cash.
FY26: operating cash of ₹15,316 Cr against reported profit of ₹8,188 Cr, leaving free cash of ₹3,934 Cr after ₹11,382 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 174% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 174%: the cash cycle stretched 19 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 4.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
UltraTech Cement Ltd's cash conversion cycle runs 13 days in FY26, up from −6 days in FY21. Capital spending ran ₹55,721 Cr over the last 3 years. At FY26 sales of ₹88,512 Cr each day of that cycle holds about ₹242 Cr, so roughly ₹3,152 Cr sits inside the business at any moment.
FY26: debtors at 25 days, inventory at 206 days — roughly 6.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 13 days, looser than FY21's −6.
The full loop: cash goes out to suppliers and production on day 0; stock waits 206 days to sell; customers pay about 25 days after that; and suppliers themselves are paid at 217 days — netting out to the 13-day cycle.
In money terms: at FY26 sales of ₹88,512 Cr, each day of the cycle holds about ₹242 Cr — so the 13-day loop keeps roughly ₹3,152 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹55,721 Cr over the last 3 fiscal years against ₹11,804 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹8,742 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
UltraTech Cement Ltd earns a ROCE of 13% in FY26. That is up from a trough of 10% in FY19. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 9.3% net margin on 0.63× asset turns.
FY26 ROCE is 13%, recovered from a FY19 trough of 10% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 9.3% net margin × 0.63× asset turns × 1.84× balance-sheet leverage ≈ 10.8% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 17% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
UltraTech Cement Ltd carries ₹23,755 Cr of borrowings against ₹76,624 Cr of equity in FY26, a debt-to-equity of 0.31. Operating profit covers the interest bill 9×. Over 5 years borrowings went from ₹21,719 Cr to ₹23,755 Cr. Capital spending ran ₹55,721 Cr across the last 3 of those years.
FY26: borrowings of ₹23,755 Cr against equity of ₹76,624 Cr — a debt-to-equity of 0.31. Operating profit covers the interest bill 9×. Over 5 years borrowings went from ₹21,719 Cr to ₹23,755 Cr while capital spending ran ₹55,721 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 17% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 5.9 points of UltraTech Cement Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 19.7% of the company. Foreign institutions moved −5.8 points over the same window, to 12.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +5.9 points over 8 quarters to 19.7%; Foreign institutions: −5.8 points over 8 quarters to 12.4%; Promoters: −0.6 points over 8 quarters to 59.3%.
Why the register moved: rotation — foreign institutions −5.8 points against domestic institutions +5.9 points over 8 quarters, with promoters −0.6 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
UltraTech Cement Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Star Cement LtdSTARCEMENT | 69.7/100Favorable setup94% evidence | BASING | 25.6/35 Revenue 14.5% · PAT 55.1% · OPM change -4 pp 100% evidence | 20.2/25 ROCE 16.6% · OPM 21% 100% evidence | 11.0/20 P/E 20.9× · PEG 1.11 100% evidence | 12.9/20 RS sector 13.8% · RS bench -10.3% · 1Y -33.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 25.6 + 20.2 + 11 + 12.9 = 69.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2NCL Industries LtdNCLIND | 66.9/100Favorable setup87% evidence | ASLEEP | 23.2/35 Revenue 3.7% · PAT 100% · OPM change -3 pp 95% evidence | 18.1/25 ROCE 14.6% · OPM 12% 95% evidence | 14.9/20 P/E 6.4× · PEG — 50% evidence | 10.7/20 RS sector 3.2% · RS bench -5.3% · 1Y -18.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 23.2 + 18.1 + 14.9 + 10.7 = 66.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Rain Industries LtdRAIN | 64.7/100Mixed-positive evidence75% evidence | LEADER | 28.4/35 Revenue 17% · PAT 100% · OPM change 5 pp 95% evidence | 10.5/25 ROCE 8.3% · OPM 19% 76% evidence | 10.8/20 P/E 13.5× · PEG — 15% evidence | 15.0/20 RS sector 53% · RS bench 41.8% · 1Y 55.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 28.4 + 10.5 + 10.8 + 15 = 64.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4UltraTech Cement Ltdthis pageULTRACEMCO | 63.5/100Mixed-positive evidence76% evidence | TURNING | 23.1/35 Revenue 17.2% · PAT 26.7% · OPM change -1 pp 95% evidence | 17.1/25 ROCE 12.7% · OPM 20% 76% evidence | 9.6/20 P/E 37.6× · PEG — 50% evidence | 13.7/20 RS sector 17% · RS bench -5.5% · 1Y -12.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 23.1 + 17.1 + 9.6 + 13.7 = 63.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Mangalam Cement LtdMANGLMCEM | 63.4/100Mixed-positive evidence100% evidence | TURNING | 18.1/35 Revenue 0.5% · PAT 90% · OPM change -5 pp 100% evidence | 10.5/25 ROCE 11% · OPM 12% 100% evidence | 15.2/20 P/E 21.7× · PEG 0.6 100% evidence | 19.6/20 RS sector 32.9% · RS bench 23% · 1Y 33.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 10.5 + 15.2 + 19.6 = 63.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Orient Cement LtdORIENTCEM | 58.1/100Mixed-positive evidence93% evidence | BASING | 17.9/35 Revenue -12.1% · PAT -19.3% · OPM change 3 pp 100% evidence | 16.9/25 ROCE 16.5% · OPM 24% 100% evidence | 16.1/20 P/E 12.1× · PEG 0.25 65% evidence | 7.2/20 RS sector -11.4% · RS bench -19.2% · 1Y -43.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 16.9 + 16.1 + 7.2 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7HeidelbergCement India LtdHEIDELBERG | 55.7/100Mixed-positive evidence100% evidence | TURNING | 15.7/35 Revenue 6.6% · PAT 2.6% · OPM change -4 pp 100% evidence | 14.8/25 ROCE 14.7% · OPM 11% 100% evidence | 13.2/20 P/E 27.9× · PEG 0.83 100% evidence | 12.0/20 RS sector -0.9% · RS bench -9.3% · 1Y -30.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 14.8 + 13.2 + 12 = 55.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Dalmia Bharat LtdDALBHARAT | 55.1/100Mixed-positive evidence94% evidence | BREAKING OUT | 14.1/35 Revenue 7.6% · PAT 0.4% · OPM change -3 pp 100% evidence | 13.2/25 ROCE 7.6% · OPM 21% 100% evidence | 15.1/20 P/E 29.8× · PEG 0.72 100% evidence | 12.7/20 RS sector 12.6% · RS bench -9.4% · 1Y -27.5%1 of 10 weeks ahead 70% evidence |
| Exact sum: 14.1 + 13.2 + 15.1 + 12.7 = 55.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 9JSW Cement LtdJSWCEMENT | 51.9/100Thin evidence · provisional52% evidence | ASLEEP | 19.2/35 Revenue 15.6% · PAT 100% · OPM change -5 pp 71% evidence | 11.8/25 ROCE 11.1% · OPM 16% 76% evidence | 10.6/20 P/E 20.6× · PEG — 15% evidence | 10.3/20 RS sector — · RS bench -4.9% · 1Y -20.8%3 of 10 weeks ahead 25% evidence |
| Exact sum: 19.2 + 11.8 + 10.6 + 10.3 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Nuvoco Vistas Corporation LtdNUVOCO | 49.5/100Mixed-negative evidence87% evidence | TURNING | 21.8/35 Revenue 9.5% · PAT 100% · OPM change 0 pp 100% evidence | 10.2/25 ROCE 7% · OPM 18% 100% evidence | 4.8/20 P/E 28.4× · PEG 8.14 65% evidence | 12.7/20 RS sector 3.6% · RS bench -2.8% · 1Y -28.8%5 of 10 weeks ahead 70% evidence |
| Exact sum: 21.8 + 10.2 + 4.8 + 12.7 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11J K Cements LtdJKCEMENT | 48.1/100Mixed-negative evidence94% evidence | TURNING | 11.9/35 Revenue 15.9% · PAT -7.1% · OPM change -5 pp 100% evidence | 16.7/25 ROCE 15.1% · OPM 16% 100% evidence | 8.0/20 P/E 38.3× · PEG 1.46 100% evidence | 11.5/20 RS sector 10.4% · RS bench -12.1% · 1Y -27%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11.9 + 16.7 + 8 + 11.5 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Prism Johnson LtdPRSMJOHNSN | 47.2/100Mixed-negative evidence61% evidence | BASING | 18.1/35 Revenue 4.8% · PAT 100% · OPM change 2 pp 71% evidence | 6.9/25 ROCE 5.9% · OPM 12% 76% evidence | 9.2/20 P/E 48.6× · PEG — 15% evidence | 13.0/20 RS sector 14.3% · RS bench -10.5% · 1Y -22.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.1 + 6.9 + 9.2 + 13 = 47.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13JK Lakshmi Cement LtdJKLAKSHMI | 44.8/100Mixed-negative evidence69% evidence | BASING | 14.6/35 Revenue 8.7% · PAT 0.5% · OPM change -4 pp 95% evidence | 14.1/25 ROCE 12% · OPM 14% 76% evidence | 10.7/20 P/E 16.3× · PEG — 15% evidence | 5.4/20 RS sector -8.2% · RS bench -25.2% · 1Y -45.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.6 + 14.1 + 10.7 + 5.4 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Birla Corporation LtdBIRLACORPN | 44.5/100Mixed-negative evidence94% evidence | BASING | 18.6/35 Revenue 3.9% · PAT 44.6% · OPM change -1 pp 100% evidence | 11.0/25 ROCE 9.8% · OPM 13% 100% evidence | 9.8/20 P/E 11.4× · PEG 3.92 100% evidence | 5.1/20 RS sector -14% · RS bench -17.8% · 1Y -35.5%0 of 9 weeks ahead 70% evidence |
| Exact sum: 18.6 + 11 + 9.8 + 5.1 = 44.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Shree Cement LtdSHREECEM | 44.2/100Mixed-negative evidence100% evidence | ASLEEP | 15.4/35 Revenue 12.6% · PAT 9.9% · OPM change -5 pp 100% evidence | 13.3/25 ROCE 10.3% · OPM 20% 100% evidence | 9.5/20 P/E 50× · PEG 0.96 100% evidence | 6.0/20 RS sector -4.1% · RS bench -12.1% · 1Y -24.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 13.3 + 9.5 + 6 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16India Cements LtdINDIACEM | 44.1/100Mixed-negative evidence75% evidence | ASLEEP | 21.0/35 Revenue 7% · PAT 100% · OPM change 7 pp 74% evidence | 3.7/25 ROCE 1.2% · OPM 15% 100% evidence | 6.3/20 P/E 79.6× · PEG — 50% evidence | 13.1/20 RS sector 20% · RS bench -12% · 1Y -12.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 3.7 + 6.3 + 13.1 = 44.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17ACC LtdACC | 42.6/100Mixed-negative evidence94% evidence | BASING | 9.4/35 Revenue 11.6% · PAT -21.1% · OPM change -5 pp 100% evidence | 9.8/25 ROCE 11.2% · OPM 8% 100% evidence | 16.8/20 P/E 12.3× · PEG 0.92 100% evidence | 6.6/20 RS sector -6.7% · RS bench -18.5% · 1Y -31.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.4 + 9.8 + 16.8 + 6.6 = 42.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18K C P LtdKCP | 42.6/100Mixed-negative evidence81% evidence | BASING | 7.8/35 Revenue 6.5% · PAT -17.1% · OPM change -8 pp 95% evidence | 14.3/25 ROCE 12.2% · OPM 8% 95% evidence | 13.2/20 P/E 11.8× · PEG — 50% evidence | 7.3/20 RS sector -14% · RS bench -3.9% · 1Y -20.3%1 of 11 weeks ahead 70% evidence |
| Exact sum: 7.8 + 14.3 + 13.2 + 7.3 = 42.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Shiva Cement LtdSHIVACEM | 41.0/100Thin evidence · provisional58% evidence | 23.0/35 Revenue 49.5% · PAT 22.5% · OPM change 13.9 pp 71% evidence | 4.5/25 ROCE -1.4% · OPM 12% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -27.5% · RS bench -20.8% · 1Y -44.7%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 23 + 4.5 + 10 + 3.5 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20The Ramco Cements LtdRAMCOCEM | 40.6/100Mixed-negative evidence94% evidence | BASING | 18.3/35 Revenue 8.6% · PAT 100% · OPM change -6 pp 100% evidence | 9.2/25 ROCE 6.1% · OPM 13% 100% evidence | 1.1/20 P/E 107× · PEG 4.14 100% evidence | 12.0/20 RS sector 11.1% · RS bench -11.1% · 1Y -19%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.3 + 9.2 + 1.1 + 12 = 40.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Ambuja Cements LtdAMBUJACEM | 40.0/100Mixed-negative evidence82% evidence | BASING | 10.6/35 Revenue 7.1% · PAT -5.9% · OPM change -2 pp 95% evidence | 11.0/25 ROCE 5.6% · OPM 17% 76% evidence | 12.4/20 P/E 20.7× · PEG — 50% evidence | 6.0/20 RS sector -10.3% · RS bench -17.9% · 1Y -30.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.6 + 11 + 12.4 + 6 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Deccan Cements LtdDECCANCE | 39.5/100Mixed-negative evidence80% evidence | TURNING | 13.9/35 Revenue 39.4% · PAT -48.2% · OPM change -10.8 pp 95% evidence | 7.4/25 ROCE 3.3% · OPM 7.7% 95% evidence | 9.9/20 P/E 28.1× · PEG — 15% evidence | 8.3/20 RS sector -10.4% · RS bench -18.5% · 1Y -47%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 7.4 + 9.9 + 8.3 = 39.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Sagar Cements LtdSAGCEM | 35.9/100Mixed-negative evidence72% evidence | ASLEEP | 20.0/35 Revenue 13.4% · PAT 79.7% · OPM change -8 pp 95% evidence | 5.0/25 ROCE 2% · OPM 10% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.9/20 RS sector -16.6% · RS bench -23.7% · 1Y -50.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 5 + 10 + 0.9 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24BIGBLOC Construction LtdBIGBLOC | 34.2/100Adverse evidence72% evidence | BASING | 18.6/35 Revenue 33.5% · PAT 11.3% · OPM change 5.6 pp 71% evidence | 6.0/25 ROCE 1.9% · OPM 7.9% 95% evidence | 8.5/20 P/E 344× · PEG — 15% evidence | 1.1/20 RS sector -15.2% · RS bench -22.3% · 1Y -33.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 6 + 8.5 + 1.1 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Saurashtra Cement LtdSAURASHCEM | 34.1/100Adverse evidence80% evidence | ASLEEP | 14.5/35 Revenue 7.9% · PAT -52.1% · OPM change -3.7 pp 95% evidence | 5.2/25 ROCE 2.5% · OPM 4.5% 95% evidence | 9.4/20 P/E 38× · PEG — 15% evidence | 5.0/20 RS sector -15.8% · RS bench -23.5% · 1Y -53.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 5.2 + 9.4 + 5 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Shree Digvijay Cement Co. LtdSHREDIGCEM | 32.1/100Adverse evidence81% evidence | BASING | 11.9/35 Revenue 19.6% · PAT -35% · OPM change -3.5 pp 95% evidence | 8.4/25 ROCE 6.4% · OPM 8.7% 95% evidence | 5.5/20 P/E 56.3× · PEG — 50% evidence | 6.3/20 RS sector -12.4% · RS bench -10.6% · 1Y -24.1%1 of 10 weeks ahead 70% evidence |
| Exact sum: 11.9 + 8.4 + 5.5 + 6.3 = 32.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is UltraTech Cement Ltd's share price today?
UltraTech Cement Ltd trades at ₹11,000, −11.1% over the past year. The company is valued at ₹3,24,147 Cr. The stock sits at 16% of its 52-week range of ₹10,616–₹12,963, −5.9% versus its 200-day average. On the tape, the price is building a base, 6 weeks in. — as of 11 September 2026.
What were UltraTech Cement Ltd's latest quarterly results?
UltraTech Cement Ltd reported revenue of ₹24,648 Cr and net profit of ₹2,604 Cr for the Jun 26 quarter. Revenue rose 15.9% and profit rose 17.2% year on year. Earnings per share were ₹88.21. The operating margin was 20.0%, 1.0 pp lower than a year earlier. — as of 11 September 2026.
What is UltraTech Cement Ltd's revenue?
UltraTech Cement Ltd reported revenue of ₹24,648 Cr in the Jun 26 quarter, +15.9% year on year. For the full FY26 fiscal year, revenue was ₹88,512 Cr (+16.5%). Over the last 10 years revenue compounded at 13.4% a year. — as of 11 September 2026.
What is UltraTech Cement Ltd's profit?
UltraTech Cement Ltd earned ₹2,604 Cr of net profit in the Jun 26 quarter, +17.2% year on year — the 6th straight quarter of growth. Full-year FY26 profit was ₹8,188 Cr. The operating margin ran 20.0% in the latest quarter. — as of 11 September 2026.
What is UltraTech Cement Ltd's market cap?
UltraTech Cement Ltd's market capitalisation is ₹3,24,147 Cr at a share price of ₹11,000. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is UltraTech Cement Ltd's P/E ratio?
UltraTech Cement Ltd trades at a P/E of 37.6×, at the 41st percentile of its own 11-year range, against a long-run median of 40.5×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does UltraTech Cement Ltd pay a dividend?
Yes — UltraTech Cement Ltd's dividend payout was 87% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is UltraTech Cement Ltd overvalued?
On its own history, UltraTech Cement Ltd looks mid-range: its P/E of 37.6× sits at the 41st percentile of its 11-year range (long-run median 40.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is UltraTech Cement Ltd growing?
Yes — UltraTech Cement Ltd is growing: latest-quarter revenue +15.9% year on year, profit +17.2%, and the margin −1.0 pp at 20.0%. The 10-year compound rates are 13.4% (revenue) and 12.7% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is UltraTech Cement Ltd performing?
UltraTech Cement Ltd is building a base, 6 weeks in. Its latest quarter's revenue rose 15.9% and profit rose 17.2% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is UltraTech Cement Ltd in?
Turning around — profit growth swung from −9.2% at the trough to +26.7% off a 5-quarter-old trough, ROCE holding at 13.0%. The read comes from the last 12 quarters of growth (revenue growth +17.2% latest, profit growth +26.7% latest, eps growth +25.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is UltraTech Cement Ltd in an uptrend?
No — the price is building a base (week 6 of stage 1), trading −5.9% versus its 200-day average and at 16% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is UltraTech Cement Ltd beating the market?
Not lately — on a trailing-13-week view UltraTech Cement Ltd is currently behind the NIFTY 500 (2 weeks and counting; last ahead the week of 2026-08-28), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +297% against the NIFTY 500's +273% — ahead of the index over the full window. — as of 11 September 2026.
Will UltraTech Cement Ltd's share price go up?
This page publishes no price forecast for UltraTech Cement Ltd. What it measures instead: the share price is ₹11,000, the price is building a base 6 weeks in. Its P/E of 37.6× sits at the 41st percentile of its own 11-year range. — as of 11 September 2026.
Who owns UltraTech Cement Ltd?
Promoters hold 59.3% of UltraTech Cement Ltd, foreign institutions 12.4%, domestic institutions 19.7% and the public 8.4% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 5.9 points over 8 quarters. — as of 11 September 2026.
Does UltraTech Cement Ltd have too much debt?
It is moderate — UltraTech Cement Ltd's debt-to-equity is 0.31, and operating profit covers the interest bill 9×. FY26 borrowings were ₹23,755 Cr against equity of ₹76,624 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is UltraTech Cement Ltd's capex?
UltraTech Cement Ltd spent ₹55,721 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹11,382 Cr, with ₹8,742 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is UltraTech Cement Ltd's cash flow?
UltraTech Cement Ltd generated ₹15,316 Cr of operating cash flow in FY26 and ₹3,934 Cr of free cash flow after ₹11,382 Cr of capital spending. Reported profit that year was ₹8,188 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is UltraTech Cement Ltd's profit real cash?
Yes — over the last 3 fiscal years, 174% of UltraTech Cement Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹15,316 Cr against reported profit of ₹8,188 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is UltraTech Cement Ltd in its business cycle?
UltraTech Cement Ltd's FY26 operating margin was 19.0%, against a 13-year band of 17.0%–26.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does UltraTech Cement Ltd's price assume?
At its price on 13 June 2026, UltraTech Cement Ltd was priced for profit growth of about 23.7% a year. Profit itself has compounded 12.7% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the UltraTech Cement Ltd story?
The sharpest disagreement: annual EPS moved +35.2% against a −11.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is UltraTech Cement Ltd a stock worth studying right now?
This is not investment advice. The machine read: UltraTech Cement Ltd's earnings have outrun its stock. EPS grew +35.2% in a year against a −11.1% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!